Traws Pharma, Inc. (NASDAQ:TRAW) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) have received an average rating of “Reduce” from the five analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $1.00.

A number of equities analysts have weighed in on TRAW shares. LADENBURG THALM/SH SH downgraded shares of Traws Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 15th. Wall Street Zen upgraded shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Traws Pharma in a report on Wednesday. Citigroup lowered shares of Traws Pharma to a “neutral” rating in a research note on Monday, June 15th. Finally, HC Wainwright reissued a “neutral” rating and set a $1.00 target price on shares of Traws Pharma in a report on Tuesday, August 18th.

Hedge Funds Weigh In On Traws Pharma

Hedge funds have recently made changes to their positions in the stock. Ikarian Capital LLC lifted its holdings in Traws Pharma by 2,280.0% during the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after purchasing an additional 649,649 shares in the last quarter. Squadron Capital Management LLC purchased a new position in Traws Pharma during the 4th quarter valued at about $806,000. Boothbay Fund Management LLC purchased a new position in Traws Pharma during the 4th quarter valued at about $220,000. Adage Capital Partners GP L.L.C. increased its position in shares of Traws Pharma by 121.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock valued at $825,000 after buying an additional 400,000 shares during the period. Finally, XTX Topco Ltd increased its position in shares of Traws Pharma by 294.2% during the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after buying an additional 31,502 shares during the period. 7.95% of the stock is currently owned by hedge funds and other institutional investors.

Traws Pharma Price Performance

Shares of NASDAQ TRAW opened at $0.59 on Friday. The stock has a market capitalization of $9.07 million, a PE ratio of -0.34 and a beta of 1.57. Traws Pharma has a one year low of $0.43 and a one year high of $3.27. The business’s fifty day moving average price is $0.63 and its 200-day moving average price is $1.26.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.18. As a group, equities analysts expect that Traws Pharma will post -1.2 EPS for the current fiscal year.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.